| Nanotechnology applications in neuroscience: Advances, opportunities and challenges | Feyza ARICIOĞLU, Salih GUMRU, Mesut ÇETİN | 115–120 |
| An open-label study of aripiprazole for methamphetamine induced psychosis | Jesjeet Singh GİLL, Ng Chong GUAN, Mohamad Hussian HABİL, Nor Zuraida ZAİNAL, Mas Ayu SAİD, Ahmad Hatim SULAİMAN | 121–129 |
| Comparison of polypharmacy in schizophrenia and other psychotic disorders in outpatient and npatient treatment periods: a naturalistic one year follow-up study | Sibel ORSEL, Hasan KARADAĞ, Hakan TÜRKCAPINAR, Olga GÜRİZ, Uğur HATİLOĞLU, Akfer KAHİLOĞULLARI KARAOĞLAN, Serkan AKKAYUNLU | 130–138 |
| Nephrotoxic effects of chronically administered olanzapine and risperidone in male rats | Onur Burak DURSUN, Zekai HALİCİ, Abdulmecit ALBAYRAK, Jale SELLİ, Deniz ÜNAL, Bünyamin ÜNAL, Selma AKSAK, Osman Nuri KELEŞ, Elif ORAL, Mustafa GÜLEÇ, Halil ÖZCAN | 139–147 |
| Treatment duration is associated with unctioning and prognosis in children with attention deficit hyperactivity disorder | Sezen KÖSE, Öznur AKYOL, Cahide AYDIN, Ayşe KUTLU, Sibel DURAK, Eyyüp Sabri ERCAN | 148–160 |
| Comparison of symptoms of pediatric bipolar disorder in the manic phase and attention deficit and hyperactivity disorder | Ömer Faruk AKCA, Şahin BODUR, Murat YÜCE, Mehmet Fatih CEYLAN | 161–166 |
| Depression, anxiety disorders, quality of life and stress coping strategies in hemodialysis and continuous ambulatory peritoneadialysis patients | Hayriye BAYKAN, İlhan YARGIÇ | 167–176 |
| Parasuicidal patients in the emergency department and their relationship with cannabinoid gene polymorphism | Mehmet Çağrı GÖKTEKİN, Şükrü GÜRBÜZ, Mehmet Nuri BOZDEMİR, Mehmet AYRANCI, Mustafa YILDIZ, Murat KARA, Bilge KARA, Mücahit EMET | 177–183 |
| Olanzapine-induced neuroleptic malignant syndrome with hypernatremia | Hüseyin GÜNAY, Recep TÜTÜNCÜ, Hakan BİLBEY | 184–186 |
| Bupropion kullanımıyla ilişkili görsel halüsinasyon: Bir olgu sunumu | Sevda KORKMAZ, Sadullah SAĞLAM, Murat ATMACA, Murat KULOĞLU | 187–189 |
|